Inflammation and atherosclerosis: role of C-Reactive protein in risk assessment
- 1 March 2004
- journal article
- review article
- Published by Elsevier BV in American Journal Of Medicine
- Vol. 116 (6), 9-16
- https://doi.org/10.1016/j.amjmed.2004.02.006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rosuvastatin in the Primary Prevention of Cardiovascular Disease Among Patients With Low Levels of Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive ProteinCirculation, 2003
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular EventsCirculation, 2003
- Markers of Inflammation and Cardiovascular DiseaseCirculation, 2003
- Inflammation in atherosclerosisNature, 2002
- Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular EventsNew England Journal of Medicine, 2002
- Inflammation and AtherosclerosisCirculation, 2002
- C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in WomenNew England Journal of Medicine, 2000
- Acute-Phase Proteins and Other Systemic Responses to InflammationNew England Journal of Medicine, 1999
- Lipids, risk factors and ischaemic heart diseaseAtherosclerosis, 1996